Lupenone

目录号: HY-N2590 纯度: 99.74%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Lupenone 是一种具有口服活性的可从 Musa basjoo 中分离出的 lupine 型三萜类化合物。Lupenone Lupenone 可通过 PI3K/Akt/mTOR 及 NF-κB 信号通路发挥作用。Lupenone 具有抗炎、抗病毒、抗糖尿病和抗癌活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Lupenone Chemical Structure

CAS No. : 1617-70-5

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
1 mg	￥700	In-stock
5 mg	￥1700	In-stock
10 mg	￥2600	In-stock
25 mg	￥4413	In-stock
50 mg	现货	询价
100 mg	现货	询价
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Lupenone 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Parasite 亚型特异性产品:

查看所有亚型

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

查看 PI3K 亚型特异性产品:

查看所有亚型

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

查看 Akt 亚型特异性产品:

查看所有亚型

Akt Akt1 Akt2 Akt3

查看 mTOR 亚型特异性产品:

查看所有亚型

mTOR mTORC1 mTORC2

查看 NF-κB 亚型特异性产品:

查看所有亚型

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

生物活性
纯度 & 产品资料
参考文献

生物活性

Lupenone is an orally active lupine-type triterpenoid that can be isolated from Musa basjoo. Lupenone Lupenone plays a role through the PI3K/Akt/mTOR and NF-κB signaling pathways. Lupenone has anti-inflammatory, antiviral, antidiabetic and anticancer activities^[1]^[2]^[3].

IC₅₀ & Target

Trypanosoma

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
B16	ED₅₀	0.35 μM Compound: 2	Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days	[PMID: 12027734]
B16	IC₅₀	25.4 μM Compound: 2	Growth inhibition of mouse B16 2F2 cells after 3 days Growth inhibition of mouse B16 2F2 cells after 3 days	[PMID: 12027734]
CHO	EC₅₀	> 10 μM Compound: Lupenone	Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay	[PMID: 19911773]
COS-1	EC₅₀	0 μM Compound: Lupenone	Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay	[PMID: 19911773]
DU-145	CC₅₀	> 500 μM Compound: 4	Cytotoxic activity in human DU145 cells by sulforhodamine B assay Cytotoxic activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
DU-145	IC₅₀	> 500 μM Compound: 4	Antiproliferative activity in human DU145 cells by sulforhodamine B assay Antiproliferative activity in human DU145 cells by sulforhodamine B assay	[PMID: 29120172]
HEK293	CC₅₀	> 500 μM Compound: 4	Cytotoxic activity in HEK293 cells by sulforhodamine B assay Cytotoxic activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HEK293	IC₅₀	> 500 μM Compound: 4	Antiproliferative activity in HEK293 cells by sulforhodamine B assay Antiproliferative activity in HEK293 cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	IC₅₀	> 10 μg/mL Compound: lupenone	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 16038541]
HeLa	CC₅₀	> 500 μM Compound: 4	Cytotoxic activity in human HeLa cells by sulforhodamine B assay Cytotoxic activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HeLa	IC₅₀	> 500 μM Compound: 4	Antiproliferative activity in human HeLa cells by sulforhodamine B assay Antiproliferative activity in human HeLa cells by sulforhodamine B assay	[PMID: 29120172]
HEp-2	IC₅₀	> 10 μg/mL Compound: lupenone	Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay Cytotoxicity against human Hep2 cells after 48 hrs by MTT assay	[PMID: 16038541]
HEp-2	CC₅₀	> 500 μM Compound: 4	Cytotoxic activity in human Hep2 cells by sulforhodamine B assay Cytotoxic activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
HEp-2	IC₅₀	> 500 μM Compound: 4	Antiproliferative activity in human Hep2 cells by sulforhodamine B assay Antiproliferative activity in human Hep2 cells by sulforhodamine B assay	[PMID: 29120172]
J774.A1	IC₅₀	38.8 μM Compound: 2	Antiinflammatory activity in mouse J774A1 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse J774A1 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method	[PMID: 24909081]
KB	CC₅₀	> 500 μM Compound: 4	Cytotoxic activity in human KB cells by sulforhodamine B assay Cytotoxic activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
KB	IC₅₀	> 500 μM Compound: 4	Antiproliferative activity in human KB cells by sulforhodamine B assay Antiproliferative activity in human KB cells by sulforhodamine B assay	[PMID: 29120172]
L6	IC₅₀	> 90 μM Compound: 10	Cytotoxicity against rat L6 cells after 72 hrs by microplate fluorimetry Cytotoxicity against rat L6 cells after 72 hrs by microplate fluorimetry	[PMID: 21438586]
MCF7	CC₅₀	> 500 μM Compound: 4	Cytotoxic activity in human MCF7 cells by sulforhodamine B assay Cytotoxic activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MCF7	IC₅₀	> 500 μM Compound: 4	Antiproliferative activity in human MCF7 cells by sulforhodamine B assay Antiproliferative activity in human MCF7 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	CC₅₀	> 500 μM Compound: 4	Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
MDA-MB-231	IC₅₀	> 500 μM Compound: 4	Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay	[PMID: 29120172]
RAW264.7	IC₅₀	> 0.4 μM Compound: lupenone	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release after 24 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release after 24 hrs	[PMID: 20192236]
RAW264.7	IC₅₀	38.5 μM Compound: 2	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method	[PMID: 24909081]
SiHa	CC₅₀	> 500 μM Compound: 4	Cytotoxic activity in human SiHa cells by sulforhodamine B assay Cytotoxic activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
SiHa	IC₅₀	> 500 μM Compound: 4	Antiproliferative activity in human SiHa cells by sulforhodamine B assay Antiproliferative activity in human SiHa cells by sulforhodamine B assay	[PMID: 29120172]
Vero	IC₅₀	> 10 μg/mL Compound: lupenone	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	[PMID: 16038541]
Vero	CC₅₀	> 500 μM Compound: 4	Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]
Vero	IC₅₀	> 500 μM Compound: 4	Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay	[PMID: 29120172]

体外研究
(In Vitro)

Lupenone (40 μM, 1 h) 通过 PI3K/Akt/mTOR 信号通路保护神经母细胞瘤 SH-SY5y 细胞免受甲基苯丙胺诱导的凋亡细胞死亡^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	SH-SY5y
Concentration:	5, 10. 20, 40 μM
Incubation Time:	24 h
Result:	Did not cause significant cell death at different concentrations.

Apoptosis Analysis^[1]

Cell Line:	SH-SY5y
Concentration:	40 μM
Incubation Time:	1 h
Result:	Reduced the population of annexinV/PI-positive cells (early apoptotic cells) and annexinV positive cells (total apoptotic cells).

Western Blot Analysis^[1]

Cell Line:	SH-SY5y
Concentration:	40 μM
Incubation Time:	1 h
Result:	Increased the expression of anti-apoptotic proteins, including bcl-2 and caspases such as caspase 3, caspase 7, and caspase 8. Recuperate the phosphorylation level of PI3K and Akt. Inhibited the translocation of p65 from the cytosol to the nucleus, IκBα degradation, and IκBα phosphorylation.

体内研究
(In Vivo)

Lupenone (6, 12, 24 mg/kg/day, 灌胃, 连续 6 周) 通过调节 NF-κB 通路介导的炎症和 TGF-β1/Smad/ CTGF 相关纤维化改善 2 型糖尿病肾病^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Spontaneous type 2 diabetic nephropathy db/db mouse models^[1]
Dosage:	6, 12, 24 mg/kg
Administration:	i.g.
Result:	Maintained the fasting blood glucose. Reduced glycosylated hemoglobin, insulin, and 24 h proteinuria levels. Regulated changes in biochemical indicators

分子量

424.70

Formula

C₃₀H₄₈O

CAS 号

1617-70-5

性状

固体

颜色

White to off-white

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

Ethanol 中的溶解度 : 10 mg/mL (23.55 mM; 超声助溶 (<60°C))

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3546 mL	11.7730 mL	23.5460 mL
5 mM	0.4709 mL	2.3546 mL	4.7092 mL
10 mM	0.2355 mL	1.1773 mL	2.3546 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (2.35 mM); 澄清溶液

此方案可获得 ≥ 1 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% EtOH 90% Corn Oil
Solubility: ≥ 1 mg/mL (2.35 mM); 澄清溶液

此方案可获得 ≥ 1 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

纯度 & 产品资料

纯度: 99.74%

选择批次：

Data Sheet (637 KB) SDS (393 KB)

COA (198 KB) HNMR (264 KB) RP-HPLC (214 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Lee HS, et al. Lupenone Protects Neuroblastoma SH-SY5y Cells Against Methamphetamine-Induced Apoptotic Cell Death via PI3K/Akt/mTOR Signaling Pathway. Int J Mol Sci. 2020 Feb 27;21(5):1617. [Content Brief]

[2]. Wu H, et al. Lupenone improves type 2 diabetic nephropathy by regulating NF-κB pathway-mediated inflammation and TGF-β1/Smad/CTGF-associated fibrosis. Phytomedicine. 2023 Sep;118:154959. [Content Brief]

[3]. Mukerjee N, et al. Dynamics of natural product Lupenone as a potential fusion inhibitor against the spike complex of novel Semliki Forest Virus. PLoS One. 2022 Feb 25;17(2):e0263853. [Content Brief]

Lupenone 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

Ethanol	1 mM	2.3546 mL	11.7730 mL	23.5460 mL	58.8651 mL
	5 mM	0.4709 mL	2.3546 mL	4.7092 mL	11.7730 mL
	10 mM	0.2355 mL	1.1773 mL	2.3546 mL	5.8865 mL
	15 mM	0.1570 mL	0.7849 mL	1.5697 mL	3.9243 mL
	20 mM	0.1177 mL	0.5887 mL	1.1773 mL	2.9433 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

Lupenone

Customer Review